Samsung Biologics Completes 2.7 Trillion Won Rights Offering
Samsung Biologics has successfully completed a rights offering worth 2.7 trillion won, attracting record public subscription deposits.
Samsung Biologics has successfully completed a rights offering worth 2.7 trillion won, attracting record public subscription deposits.
Samsung Biologics has announced the successful completion of its rights offering valued at approximately 2.7 trillion won (about $1.9 billion). This offering, aimed at bolstering the company's position as a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, has drawn an unprecedented public subscription margin of 11.4 trillion won.
The rights offering, which took place over two days from November 12 to 13, saw a total of 9,745,071 shares subscribed, resulting in a subscription ratio of 135.6 to 1. Investors were required to deposit around 160 million won to secure one share at the issue price of 1.174 million won.
This record-breaking public interest reflects strong investor confidence in Samsung Biologics' growth strategy. The funds raised will primarily be used to acquire Polypeptide Group, a global peptide CDMO, for 1.46 billion Swiss francs (approximately 2.7 trillion won). This acquisition is expected to enhance Samsung Biologics' service offerings in the rapidly growing peptide sector.
Lee Myung-sun, a research analyst at DB Securities, noted that this acquisition will allow Samsung Biologics to enter the GLP-1 market, which is gaining traction as a treatment for obesity. The company plans to finalize the acquisition process and is optimistic about achieving synergies through its newly established European sales office.
Related companies
Where it matters
Related coverage

Celltrion Pharm Reports Increased Q3 Profit Driven by Higher Revenues

Celltrion Wins Brazil Cancer Drug Tender for Seventh Straight Year

Celltrion Launches Three New Biosimilars in Brazil
